Viking Therapeutics Inc. recently released a corporate presentation highlighting its ongoing efforts in developing novel therapeutics for metabolic and endocrine diseases. The presentation outlines multiple clinical programs, including VK2735, a GLP-1/GIP dual agonist for obesity, which successfully achieved its primary endpoint in the Phase 2 VENTURE study, with a Phase 3 trial planned for the second quarter of 2025. The oral version of VK2735 is currently in Phase 2, following positive proof-of-concept results in Phase 1. Additionally, an amylin agonist for obesity is in the pipeline, with an investigational new drug application planned for the fourth quarter of 2025. Other programs include VK2809, a selective thyroid receptor-β agonist for MASH, and VK0214, a selective thyroid receptor-β agonist for X-ALD, both of which have shown promising results in recent trials. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。